Prescriber Scope of Practice for ADHD in North Carolina

If you’re a psychiatrist or psychiatric nurse practitioner wondering whether you can legally prescribe Adderall, Ritalin, or other ADHD medications through telehealth — and what rules you need to follow — you’re in the right place.

The short answer: Yes, you can prescribe ADHD medications via telehealth through the end of 2026, thanks to federal extensions of COVID-era flexibilities. But the details matter — a lot. Federal DEA rules, state licensing requirements, and scope-of-practice laws all come into play, and they vary significantly depending on where your patient is located and what credentials you hold.

This guide breaks down exactly what you need to know: the current federal rules, state-by-state differences in our six priority markets (California, Texas, Florida, New York, Pennsylvania, and Illinois), what’s changing in 2027, and how platforms like Klarity Health handle the compliance heavy-lifting so you can focus on patient care.

The Federal Picture: Where We Stand in 2026

The Ryan Haight Act and COVID Waivers

Under normal circumstances, the Ryan Haight Online Pharmacy Consumer Protection Act requires an in-person medical evaluation before prescribing any controlled substance via telemedicine. For ADHD providers, this was a significant barrier — you couldn’t start a patient on Adderall after just a video visit.

COVID changed that. In March 2020, the DEA exercised emergency authority to waive the in-person exam requirement for Schedule II–V controlled substances prescribed via telehealth, as long as the prescription was issued for a legitimate medical purpose through a real-time, two-way audiovisual interaction.

Here’s where we are now: The DEA and HHS have extended these telehealth flexibilities through December 31, 2026. This is the fourth extension, explicitly allowing clinicians to prescribe Schedule II stimulants like Adderall or Concerta via telehealth without any prior in-person visit.

You can legally evaluate a new ADHD patient over video, make a diagnosis, and prescribe stimulant medication — all remotely — as long as you meet the standard of care and follow proper prescribing protocols (PDMP checks, electronic prescribing, etc.).

What’s Coming: Permanent DEA Rules

The DEA is finalizing permanent telemedicine prescribing regulations to replace these temporary waivers. In January 2025, they announced three new rules developed after extensive public feedback (over 38,000 comments and listening sessions with providers).

Key elements of the upcoming rules:

• Telemedicine Special Registration: A new DEA registration pathway that will allow providers to prescribe controlled substances to new patients via telehealth without an in-person exam. Requirements will include mandatory nationwide PDMP checks and strict patient identity verification during video consultations.

• Established Patient Exception: If a patient has had at least one in-person visit with you (or someone in your practice), the new telemedicine rules won’t apply — you can continue treating them remotely without additional requirements.

• Platform Registration: Telehealth companies themselves will need to register with the DEA, adding corporate-level oversight to prevent abuse.

The DEA hasn’t published final rule text yet, but these regulations are expected to take effect in 2027. The message is clear: telehealth access for ADHD treatment will continue, but with stronger safeguards around patient verification and prescription monitoring.

Bottom line for providers: Stay prepared to obtain the telemedicine special registration when it becomes available. This will be your ticket to continuing uninterrupted ADHD care via telehealth once the current blanket waiver expires.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where Location Really Matters

While federal law sets the baseline, each state adds its own layer of requirements. Here’s what you need to know for our priority states:

California: Progressive and Permissive

The good news: California doesn’t require an in-person exam beyond federal requirements. State law explicitly allows telehealth evaluations to satisfy prescribing standards — even asynchronous methods can count if clinically appropriate, though for controlled substances you’ll want a live video visit.

What you need:

• California medical license (no shortcuts — CA isn’t in the Interstate Medical Licensure Compact)
• DEA registration covering California
• Must check CURES (California’s PDMP) before the initial prescription and every 4 months for ongoing stimulant therapy

For PMHNPs: California is transitioning to Full Practice Authority. By 2026, experienced NPs (with 3 years/4,600 hours under physician oversight) can practice and prescribe independently, including stimulants. New graduates still need supervising agreements initially.

The reality: California’s Medical Board wants thorough documentation, but they’ve made clear that telehealth meets the standard. Just avoid prescribing based solely on a questionnaire without real-time interaction.

Texas: Physician-Only for Stimulants

The restriction that matters: Texas is one of the most restrictive states for nurse practitioners. APRNs and PAs cannot prescribe Schedule II controlled substances in outpatient settings — period. The only exceptions are narrow: hospital inpatients (≥24 hours), hospice patients, or ER emergency orders.

ADHD doesn’t fall under these exceptions. This means only physicians (MD/DO) can prescribe Adderall, Ritalin, or other stimulants for outpatient ADHD treatment in Texas, whether in-person or via telehealth.

For psychiatrists: Texas allows full telehealth practice for ADHD. You can establish a patient relationship via video and prescribe stimulants. Texas is part of the Interstate Medical Licensure Compact, making it easier for out-of-state physicians to get licensed.

What you need:

• Texas medical license (or IMLC pathway)
• DEA registration
• Electronic prescribing setup (mandatory for all controlled substances in Texas since 2021)
• PDMP checks are required for opioids and benzos, not technically mandated for stimulants but highly recommended

For platforms: If you’re using NPs or PAs in Texas for ADHD care, you must have physician oversight with the physician writing the actual prescriptions. At Klarity, we ensure Texas-licensed psychiatrists handle stimulant prescribing for Texas patients.

Florida: Explicitly Allowed for Mental Health

The win: Florida law has a specific carve-out. While telehealth providers generally can’t prescribe Schedule II controlled substances remotely, there’s an explicit exception for ‘treatment of a psychiatric disorder.’ ADHD qualifies.

This means Florida-licensed psychiatrists and PMHNPs can legally prescribe stimulants via telehealth without an in-person visit — it’s written into the statute.

The bonus: Florida created an out-of-state telehealth provider registration system. Providers licensed in other states can register to treat Florida patients via telehealth (including prescribing ADHD meds under the psychiatric exception) without getting a full Florida license. You need an active unrestricted license elsewhere, clean disciplinary record, and malpractice insurance.

For PMHNPs: Florida requires a protocol agreement with a supervising psychiatrist (psychiatric NPs aren’t included in the state’s independent practice law). However, PMHNPs who meet the ‘psychiatric nurse’ criteria aren’t limited to the 7-day supply restriction that applies to other APRNs prescribing Schedule II drugs — you can prescribe full 30-day supplies and beyond.

What you need:

• Florida license or out-of-state telehealth registration
• DEA registration
• Register with E-FORCSE (Florida’s PDMP) and check it before prescribing controlled substances
• Protocol agreement with a psychiatrist if you’re an NP

The practical angle: Florida’s clear statutory framework actually makes compliance easier. Just document that you’re treating a psychiatric disorder in your notes.

New York: Recently Aligned with Federal Law

The update: In May 2025, New York explicitly updated its regulations to allow controlled substance prescribing via telehealth consistent with federal law. Before this, NY had mirrored the Ryan Haight Act’s in-person requirement, but the state adjusted to align with DEA’s extended flexibilities.

What this means: As long as federal telehealth waivers are in place (through 2026), you can prescribe ADHD medications via telehealth in New York. When DEA’s permanent rules take effect, NY will require compliance with those.

What you need:

• New York medical license (no IMLC or telehealth shortcuts)
• DEA registration
• Must check I-STOP/PMP registry before prescribing any Schedule II–IV controlled substance — this is mandatory and strictly enforced
• Electronic prescribing required (NY mandated e-prescribing for all controlled substances since 2016)

For PMHNPs: New York is progressive. NPs with more than 3,600 hours of experience can practice independently without a written collaborative agreement, including full prescribing authority for stimulants. No quantity restrictions.

Provider tip: New York allows up to 90-day supplies of stimulants for ADHD if you indicate condition code ‘B’ (ADHD/minimal brain dysfunction) on the prescription. This is a huge convenience for stable patients and reduces administrative burden.

Pennsylvania: Collaborative Requirements for NPs

The baseline: Pennsylvania doesn’t have state-specific barriers to telehealth prescribing beyond federal law. The medical boards allow telehealth practice and prescribing if the encounter meets the standard of care.

For PMHNPs: Pennsylvania requires collaborative agreements with physicians. CRNPs can prescribe Schedule II controlled substances, but only up to a 30-day supply, and any continuation beyond that requires physician approval. The collaborating physician must be available for consultation and review the NP’s Schedule II prescribing monthly.

For psychiatrists: Full authority with no special limitations. Pennsylvania joined the Interstate Medical Licensure Compact in 2022, making it easier for out-of-state physicians to get licensed.

What you need:

• Pennsylvania license (IMLC available for MDs)
• DEA registration
• Electronic prescribing setup (mandatory since 2019)
• Check PA PDMP before initial prescription of any controlled substance
• Document that your telehealth evaluation meets the standard of care (the boards emphasize this)

The practical reality: If you’re an NP on a telehealth platform in Pennsylvania, you need a Pennsylvania psychiatrist partner who reviews your ADHD cases monthly and approves ongoing stimulant therapy. It’s not overly burdensome — often handled through structured case reviews — but it’s required.

Illinois: Two-Tier System for NPs

The framework: Illinois allows telehealth prescribing under federal rules with no additional state restrictions. But there’s an important distinction for nurse practitioners.

For PMHNPs (without Full Practice Authority): If you’re working under a collaborative agreement, you can prescribe a 30-day supply of Schedule II stimulants, but any continuation requires physician approval. The collaborating physician must review your Schedule II prescribing monthly.

For PMHNPs (with Full Practice Authority): Illinois allows experienced APRNs (4,000 hours of practice under collaboration plus 250 hours of additional training) to apply for Full Practice Authority. Once you have FPA status, you can prescribe stimulants independently without physician consultation.

Here’s the key detail: Illinois law requires FPA APRNs to have a ‘consultation relationship’ with a physician for Schedule II narcotic drugs (opioids) and benzodiazepines. But stimulants for ADHD are non-narcotic Schedule II substances, so this consultation requirement doesn’t apply. An FPA PMHNP in Illinois has complete autonomy for ADHD medication management.

What you need:

• Illinois medical license
• Illinois Controlled Substance License (separate from your DEA registration)
• PDMP checks recommended before prescribing (required for opioids/benzos, best practice for stimulants)
• Electronic prescribing setup

The opportunity: Illinois’s FPA pathway is a game-changer for experienced psychiatric NPs. If you meet the criteria, you can practice telehealth for ADHD with the same independence as a psychiatrist.

Quick Reference: State Telehealth Rules for ADHD Prescribing

The Economics: Why Telehealth ADHD Care Makes Sense

Here’s what providers don’t talk about enough: patient acquisition costs.

If you’re building a private practice and trying to attract ADHD patients through traditional channels, you’re looking at significant investment:

• SEO takes 6–12 months of consistent effort and expense before generating meaningful patient flow. Most solo providers don’t have the expertise or patience.

• Google Ads for mental health keywords run $15–40+ per click. Most clicks don’t convert to booked patients. Realistic cost per booked patient through PPC: $200–400+.

• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers. Zocdoc charges per booking ($35–100+), but when you add the subscription fee, total monthly costs add up quickly.

• True patient acquisition cost when you factor in agency fees, ad spend testing, staff time to handle leads, no-show rates from cold leads, and failed campaigns: $200–500+ per qualified patient.

Why Klarity’s Model Works

Klarity uses a pay-per-appointment model. You don’t pay upfront marketing spend or monthly subscriptions. Instead, you pay a standard listing fee per new patient lead — only when a qualified patient books with you.

The value proposition:

• No wasted ad spend on clicks that don’t convert
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

Instead of gambling $3,000–5,000/month on marketing with uncertain results, you get guaranteed ROI. You pay only when you’re earning.

For ADHD specifically, this matters even more. ADHD patients often need ongoing medication management — these aren’t one-time visits. Once you establish care with a patient through Klarity, that relationship continues, building your recurring revenue without ongoing acquisition costs for that patient.

What Happens in 2027?

The current federal extension runs through December 31, 2026. After that, the DEA’s permanent telemedicine rules take effect.

What to expect:

• Special registration requirement: You’ll likely need to obtain a Telemedicine Special Registration to continue prescribing to new patients without an in-person exam
• Enhanced PDMP requirements: Mandatory nationwide PDMP checks (DEA is building a national hub)
• Stricter identity verification: Formal protocols for verifying patient identity during video visits
• Platform compliance: Telehealth companies will need DEA registration, adding another layer of oversight

What won’t change: The fundamental ability to treat ADHD patients via telehealth and prescribe medications remotely. The DEA has made clear they’re preserving telehealth access while adding appropriate safeguards.

What you should do now:

• Stay current with your state’s PDMP and e-prescribing requirements
• Document thorough evaluations that meet standard of care
• Be prepared to complete the special registration process when it becomes available
• If you’re an NP, understand your state’s scope of practice and any supervision requirements

Platforms like Klarity will handle the compliance updates and ensure providers are following the latest rules as they take effect.

The Bottom Line: Telehealth ADHD Care Is Here to Stay

The regulatory landscape for telehealth ADHD prescribing is more stable than many providers realize. Federal extensions through 2026 provide certainty, and the DEA’s upcoming permanent rules are designed to maintain access while preventing abuse.

For psychiatrists, the path is straightforward: get licensed in your target states, follow federal and state prescribing protocols, and you can build a robust telehealth ADHD practice.

For PMHNPs, your autonomy varies by state. In progressive states like California, New York, and Illinois (with FPA), you have nearly the same authority as physicians. In restrictive states like Texas, you’ll need physician collaboration for prescribing. But in every state, there’s a legal pathway to provide ADHD care via telehealth.

The demand is massive. ADHD is one of the most common mental health conditions, particularly in adults who went undiagnosed as children. Telehealth removes barriers — geographic access, scheduling flexibility, stigma around visiting a psychiatrist’s office.

And here’s what matters for your practice: ADHD treatment is longitudinal. You’re not treating acute episodes; you’re managing ongoing care, medication adjustments, and supporting patients long-term. That means predictable, recurring revenue once you establish your patient panel.

Ready to Start Prescribing ADHD Medications via Telehealth?

Klarity Health connects psychiatrists and psychiatric nurse practitioners with patients who need ADHD treatment. We handle patient acquisition, scheduling, telehealth technology, and compliance support — you focus on clinical care.

What we provide:

• Pre-screened patients matched to your availability and expertise
• Integrated EHR and e-prescribing for controlled substances
• Support with state licensing and credentialing
• Ongoing compliance updates as regulations change
• Flexible scheduling — you decide when and how much you work

No upfront costs. No marketing gamble. No technology headaches.

Join hundreds of psychiatrists and PMHNPs who are building thriving telehealth practices through Klarity while providing accessible ADHD care to patients who need it.

Explore joining Klarity’s provider network →

Frequently Asked Questions

Can I prescribe Adderall via telehealth without ever seeing the patient in person?

Yes, through December 31, 2026, under the federal DEA extension. You must conduct a proper evaluation via live video (meeting the standard of care), check your state’s PDMP, and use electronic prescribing. After 2026, you’ll likely need a Telemedicine Special Registration from the DEA to continue prescribing to new patients without an in-person exam.

Do state laws allow telehealth prescribing of ADHD medications?

Most states defer to federal law. California, Florida (under the psychiatric disorder exception), New York (as of May 2025), Pennsylvania, and Illinois all permit telehealth ADHD prescribing consistent with federal rules. Texas allows it for physicians but prohibits NPs from prescribing Schedule II stimulants in outpatient settings.

Can psychiatric nurse practitioners prescribe ADHD medications via telehealth?

It depends on the state. In California, New York, and Illinois (with FPA), PMHNPs can prescribe stimulants independently or with minimal physician involvement. In Pennsylvania and Illinois (without FPA), NPs need collaborative agreements and physician approval for ongoing stimulant therapy. In Texas, NPs cannot prescribe Schedule II stimulants at all for outpatients — only physicians can.

What’s the difference between federal and state telehealth prescribing rules?

Federal law (DEA rules under the Controlled Substances Act) sets the baseline — currently allowing telehealth prescribing through 2026. State laws add additional requirements around licensing, scope of practice (especially for NPs), PDMP checks, and telehealth standards. You must comply with both.

Do I need to check the prescription drug monitoring program (PDMP) before prescribing ADHD medications?

Yes, in most states. California requires CURES checks initially and every 4 months. New York mandates I-STOP checks for every Schedule II prescription. Pennsylvania requires checks for new controlled substance courses. Even if not legally mandated in your state, checking the PDMP is best practice and expected by medical boards.

How long does it take to get licensed in multiple states for telehealth practice?

It varies. States in the Interstate Medical Licensure Compact (IMLC) can be faster for physicians — often 30–60 days. Non-compact states may take 3–6 months. Florida’s out-of-state telehealth registration can be quicker. Klarity’s credentialing team helps providers navigate multi-state licensing efficiently.

What happens if the DEA rules change in 2027?

The DEA’s permanent rules will likely require a Telemedicine Special Registration for prescribing controlled substances to new patients without an in-person exam. This will include mandatory nationwide PDMP checks and patient identity verification protocols. Telehealth platforms like Klarity will update their systems to ensure provider compliance, and we’ll guide you through any new registration requirements.

Can I prescribe 90-day supplies of ADHD medications via telehealth?

In some states, yes. New York explicitly allows 90-day stimulant prescriptions for ADHD if you indicate the condition code. Other states typically limit controlled substances to 30-day supplies. Check your specific state’s regulations. Practically, many providers stick with 30-day prescriptions for stimulants to monitor efficacy and side effects closely.

Is audio-only (phone) sufficient for prescribing ADHD medications via telehealth?

No. The DEA’s current flexibilities require live, two-way interactive audiovisual communication (video). Audio-only doesn’t meet the standard for prescribing Schedule II controlled substances via telemedicine, except in very limited circumstances (like buprenorphine for opioid use disorder). For ADHD care, use video.

How does Klarity handle compliance with different state regulations?

Klarity’s platform is built with state-specific compliance in mind. We credential providers according to each state’s requirements, integrate with state PDMPs, provide e-prescribing that meets state and federal standards, and update our systems as regulations change. Our compliance team monitors regulatory updates and communicates changes to providers proactively.

Citations and Sources

All regulatory information in this guide has been verified against official government sources and current statutes as of February 2026. The following sources were consulted:

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026). Official announcement of the fourth extension of COVID-era telehealth prescribing rules through December 31, 2026. HHS.gov

2. Healthcare Dive – DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time (January 5, 2026). Industry analysis of the 2026 extension and implications for Schedule II-V prescribing. HealthcareDive.com

3. DEA Press Release – DEA Announces Three New Telemedicine Rules to Continue Open Access (January 16, 2025). Official summary of proposed permanent telemedicine rules including special registration requirements and patient safeguards. DEA.gov

4. RxAgent Blog – NP Prescriptive Authority by State: 2026 Comprehensive Guide (Updated December 28, 2025). State-by-state analysis of nurse practitioner scope of practice and prescribing authority, including DEA proposed rules. RxAgent.co

5. New York State Department of Health – Bureau of Narcotic Enforcement Guidance on Prescribing Controlled Substances via Telehealth (Effective May 21, 2025). Official state guidance aligning New York regulations with federal telehealth flexibilities. NinthDistrict.org

Additional state-specific sources include Florida Statutes §456.47 and §464.012, Texas Board of Nursing APRN Practice FAQ, Pennsylvania Code Title 49 Chapter 21 (CRNP regulations), Illinois Administrative Code Title 68 Part 1300 (Nurse Practice Act rules), and California Business & Professions Code §2242. All citations reflect current law as of February 2026.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care